MARKET

RVMD

RVMD

Revolution Medicines, Inc.
NASDAQ
32.23
+0.51
+1.61%
After Hours: 32.23 0 0.00% 16:04 03/28 EDT
OPEN
31.58
PREV CLOSE
31.72
HIGH
32.48
LOW
31.33
VOLUME
997.44K
TURNOVER
0
52 WEEK HIGH
35.60
52 WEEK LOW
15.44
MARKET CAP
5.31B
P/E (TTM)
-8.3573
1D
5D
1M
3M
1Y
5Y
Revolution Medicines to Deliver Multiple Presentations at the Upcoming American Association for Cancer Research Annual Meeting 2024
Revolution Medicines, Inc. Is a clinical-stage oncology company developing targeted therapies for patients with RAS-addicted cancers. The company will deliver multiple presentations at the American Association for Cancer Research Annual Meeting 2024 being held April 5-10, 2024 in San Diego.
Barchart · 16h ago
S&P 500 Futures Up In Premarket Trading; Revolution Medicines, Robinhood Markets Lead
U.S. Stock markets set to open in two hours. S&P 500 futures were up 0.42% in pre-market trading. Stocks in Asia were mixed overnight. Brent crude oil futures were down 0.55% in commodities news. Bitcoin was up 1% to $70,105.
Barron‘s · 1d ago
Weekly Report: what happened at RVMD last week (0318-0322)?
Weekly Report · 3d ago
Weekly Report: what happened at RVMD last week (0311-0315)?
Weekly Report · 03/18 09:15
Revolution Medicines Initiated at Overweight by Piper Sandler
Dow Jones · 03/11 10:11
Revolution Medicines Price Target Announced at $43.00/Share by Piper Sandler
Dow Jones · 03/11 10:11
Piper Sandler Initiates Coverage On Revolution Medicines with Overweight Rating, Announces Price Target of $43
Benzinga · 03/11 10:02
Weekly Report: what happened at RVMD last week (0304-0308)?
Weekly Report · 03/11 09:14
More
About RVMD
Revolution Medicines, Inc. is a clinical-stage oncology company developing novel targeted therapies for RAS-addicted cancers. The Company’s research and development pipeline comprises RAS(ON) inhibitors that bind directly to RAS variants, which it refers to as RAS(ON) Inhibitors, and RAS companion inhibitors that target key nodes in the RAS pathway or associated pathways, which it refers to as RAS Companion Inhibitors. Its RAS(ON) Inhibitors are designed to be used as monotherapy, in combination with other RAS(ON) Inhibitors and/or in combination with RAS Companion Inhibitors or other therapeutic agents. Its RAS Companion Inhibitors are designed primarily for combination treatment strategies centered on its RAS(ON) Inhibitors. The Company’s RAS(ON) Inhibitors RMC-6236 RMC-6291 and RMC-9805 are in clinical development. RMC-6236, its RASMULTI(ON) inhibitor, is designed as a potent, oral, RAS-selective tri-complex inhibitor of multiple RAS(ON) variants, including cancer drivers.

Webull offers Revolution Medicines Inc stock information, including NASDAQ: RVMD real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, RVMD stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading RVMD stock methods without spending real money on the virtual paper trading platform.